In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emphysema: Elusive Target for Device Companies

Executive Summary

Nearly a decade into the race to arm pulmonologists with interventional tools to treat emphysema, no clear winner is emerging. Emphasys, which had led the pack in developing a bronchial valve, hit a potential roadblock at the FDA. The question is whether competitors can fill the gap.

Related Content

Rox Gets Blood Pumping in COPD
Pulmonary Device Companies Take It To The Streets - In Europe
Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
Tighter FDA Review Squeezing Device VCs
Asthmatx Positive Panel Outcome Good Sign for Pulmonology Companies
Changing Minds at the FDA
Emphysema Devices Search for Breathing Room
FDA Panel Vote on Valve Disappoints Emphasys
Devices Fill The Lung Space
Pulmonology: The Next Interventional Cardiology


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts